Takara Bio (TSE:4974) Debt-to-Asset : 0.01 (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Takara Bio Debt-to-Asset?

Takara Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円180 Mil. Takara Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円788 Mil. Takara Bio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was 円121,252 Mil. Takara Bio's debt to asset for the quarter that ended in Mar. 2024 was 0.01.

Takara Bio Debt-to-Asset Historical Data

The historical data trend for Takara Bio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takara Bio Debt-to-Asset Chart

Takara Bio Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.01

Takara Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.01	-	-	-	0.01

Competitive Comparison of Takara Bio's Debt-to-Asset

For the Biotechnology subindustry, Takara Bio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Takara Bio's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Takara Bio's Debt-to-Asset falls into.

Takara Bio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Takara Bio's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(180	+	788)	/	121252
	=	0.01

Takara Bio's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(180	+	788)	/	121252
	=	0.01

Takara Bio (TSE:4974) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Takara Bio Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Takara Bio's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Takara Bio (TSE:4974) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (TSE:4974) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

TF2:Germany

Address

Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058

Website

http://www.takara-bio.co.jp

Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.

Takara Bio (TSE:4974) Headlines

No Headlines